US regulators turn away AmgenUCBs bone drug Evenity

Amgen and UCB’s application to market boneboosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback having been turned down by US regulators.
Read the full story: Bioportfolio Latest News